Blood Pressure Control and Factors Predicting Control in a Treatment-Compliant Male Veteran Population

Pharmacotherapy

Volumn 24, Issue 2 I, 2004, Pages 179-187

  Bizien, Marcel D ^a   Jue, Sandra G ^b,c   Panning, Chad ^d   Cusack, Barry ^e   Peterson, Teri ^c  

^a MAYO CLINIC   (United States)

^b Boise VA Medical Center   (United States)

^c IDAHO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Antihypertensives; Blood pressure; Compliant; Control; Elderly; Hypertension; Simvastatin; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; COMORBIDITY; CORONARY ARTERY DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; OUTPATIENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SOLDIER;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COMORBIDITY; DEMOGRAPHY; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME; VETERANS;

EID: 1142310722     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.2.179.33136     Document Type: Article

References (27)

1. National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
2. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European working party on high blood pressure in the elderly trial. Lancet 1985;1:1349-54.
3. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the U.S. adult population: results from the third national health and nutrition examination survey, 1988-1991. Hypertension 1995;25:305-13.
4. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-86.
5. Shea S. Hypertension control, 1994. Am J Public Health 1994;84:1725-7.
6. National Heart, Lung and Blood Institute. Management of patient compliance in the treatment of hypertension: Report of the NHLBI working group. Hypertension 1982;4:415-23.
7. Borghi C, Prandin MG, Costa FV, Bachelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000;35(4):549-55.
8. Sposito A, Mansur A, Coelho O, Nicolau J, Ramires J. Additional reduction in blood pressure after cholesterol-lowering treatment with statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-9.
9. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Med Care 1988;26(8):814-23.
10. Carter BL, Saseen JJ. Hypertension. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiological approach, 5th ed. New York: McGraw-Hill, 2002:157-83.
11. National Heart, Lung and Blood Institute. CVD-related HP 2010 objectives. Available from http://hin.nhlbi.nih.gov/cvd_ frameset.htm. Accessed February 22, 2003.
12. Wannemacher AJ, Schepers GP, Townsend KA. Antihypertensive medication compliance in a Veterans Affairs healthcare system. Ann Pharmacother 2002;36:986-91.
13. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-63.
14. Psaty BM, Furberg CD, Kuller LH, et al. The association between level of blood pressure and the risk of myocardial infarction, stroke and total mortality: the cardiovascular health study. Arch Intern Med 2001;161:1183-92.
15. Hyman DJ, Pavlick VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281-6.
16. Preston RA, Materson BJ, Reda DJ, Williams DW. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs cooperative study. Arch Intern Med 2000;160(10):1449-54.
17. U.S. Department of Health and Human Services. Healthy people 2010: understanding and improving health, 2nd ed. Washington, DC: U.S. Government Printing Office, November 2000.
18. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.
19. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002;39(6):1020-5.
20. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001;14:1096-8.
21. 1 receptor function and density in hypercholesterolemic men. Circulation 1999;100:2131-4.
22. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G. Angiotensin II type I receptor antagonism improves hypercholesterolemia associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002;22:1208-12.
23. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Use of lipid lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002;4:277-85.
24. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30(11):980-7.
25. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101(12):2711-19.
26. Di Girolamo G, Gonzalez E, Livio D, de los Santos AR, Marti ML, de Gimeno MA. The effect of enalapril on PGI(2) and NO levels in hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 2002;66(5-6):493-8.
27. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6.